Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 20, 2024 3:14pm
RE:RE:RE:clinical trials
Pro-inflammatory cytokine/chemokine production by reovirus supports innate and adaptive anti-tumour immune priming https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052210/
(1191)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Apr 20, 2024 1:48pm
RE:RE:clinical trials
Article from yesterday. https://medicalxpress.com/news/2024-04-safely-boost-immune-cells-cancer.html
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 20, 2024 1:41pm
RE:Accelerated Approval, surrogate endpoints, registration
Specialty drugs, which are typically composed of large molecules that need to be injected or infused, as a category, represent roughly 50% of pharma spending today and continues to increase. Apr
...more
(850)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Apr 20, 2024 1:21pm
RE:clinical trials
Great details on the in place studies. All with the same goal. To get Pelareorep to market , to improve people's lives. Absolutely there are more. My point was from an outcome point of view, the
...more
(30)
•••
spesestsemper
X
View Profile
View Bullboard History
Post by
spesestsemper
on Apr 20, 2024 12:32pm
clinical trials
Study Details | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 20, 2024 12:01pm
RE:EU Legislative proposals aims to expedite new medicines
In addition to the EU's adoption of the new medicines proposals April 11, 2024, - on February 27, 2023, the UK government and the European Commission announced a political agreement in
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 20, 2024 11:47am
RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China
April 11, 2024 - https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?threadid=35999514
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Apr 20, 2024 11:40am
EU Legislative proposals aims to expedite new medicines
Implementation of the European Commission’s legislative proposals — Regulation 2023/0131 and Directive 2023/0132 — to replace the current EU regulatory framework for all medicines
...more
(30)
•••
spesestsemper
X
View Profile
View Bullboard History
Comment by
spesestsemper
on Apr 20, 2024 9:52am
RE:Weekend thoughts
If i might add . People are focused on roche . Our collaborator on the irene study is incyte corporation .One of our board of directors use to work for incyte . just some thoughts . INCMGA00012 and
...more
(850)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Apr 19, 2024 11:54pm
Weekend thoughts
I ponder sometimes an old sales features & benefits vs cost psychology. Applying some thinking to Onc: We know they are working to get Pela to market. The Roche study being the most aggressive
...more
(228)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Apr 19, 2024 1:33pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder
Woke goofballs the new and the old very funny .
(341)
•••
Peladawn
X
View Profile
View Bullboard History
Comment by
Peladawn
on Apr 19, 2024 12:45pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder
Poor little Bucky....you just can't get it, can you....us shareholders don't mind someone with a second opinion.....we just prefer that it's one that is substantiated by fact and possibly
...more
(151)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Apr 19, 2024 12:33pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder
The forever pumpers just can't stand someone with a different opinion. I guess they like a dictator form of rule. Reminds me of the woke goofballs.
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 19, 2024 11:16am
RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway
April 18, 2024 - AACR2024 reports that biotech has emerged from a "nuclear winter" in biotech which lasted 2 years and affected the funding environment for most biotech companies. In
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test